Full Safety Data For Female Sexual Disorder Drugs Could Come Post-Approval
Executive Summary
Sponsors of testosterone therapies for hypoactive sexual desire disorder may be able to pursue NDA approval with some safety data submitted pre-approval and further safety data collected post-approval